Amneal Pharmaceuticals Class A stock price

엠닐 파머슈티컬스NASDAQ:AMRX · Nasdaq · Healthcare · sector #14
$19.91+1.32%
2026-10-09 close · prelim
Loading chart…

Amneal Pharmaceuticals Class A's chart data is dated 2026-10-09. There is no active technical signal. There are 6 published signal records.

Amneal Pharmaceuticals Class A last closed at $19.91 (+1.32%) on 2026-10-09. Listed on Nasdaq. Trailing 12 months PER is 41.0×. Its overall grade ranks 261 of 738 stocks in Healthcare.

About this company

Amneal Pharmaceuticals Class A last closed at $19.91 (+1.32%) on 2026-10-09. Listed on Nasdaq.

Details →

Reported results

Details →

Position in sector

Healthcare · Overall B+ · 261/738

Valuation grade D

Details →

Related stocks

  • Teva Pharmaceutical IndustriesCompetitor

    제네릭·특수의약품 분야의 주요 경쟁사

  • ViatrisCompetitor

    대형 제네릭/브랜드 제네릭 경쟁사

  • Sandoz GroupCompetitor

    글로벌 제네릭 의약품 경쟁사

Details →

ETFs holding this stock

Allspring SMID Core ETF · Invesco DWA SmallCap Momentum ETF

Details →
About Amneal Pharmaceuticals Class A
What technical signals does Amneal Pharmaceuticals Class A (AMRX) have?
Amneal Pharmaceuticals Class A current technical signals: no active technical signal.
Is Amneal Pharmaceuticals Class A a cup-and-handle pattern?
No. Amneal Pharmaceuticals Class A has no valid Cup signal right now.
What published figures are available for Amneal Pharmaceuticals Class A?
Market cap: $6.26B. Trailing 12 months PER: 41.0×. Latest quarter PBR: 55.11×. Dividend yield: 0.00%.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Major stocks in the same sector

2026-10-09 dataset

Turn what you saw on this name into a strategy

Ask Q about Amneal Pharmaceuticals Class A, or open the plan table on the main site.

From the names you found to a trading rule

Tell Q about the stocks you found to place orders with your conditions.

See plans ↗

Amneal Pharmaceuticals Class A notifications

Quantus Signal · live data · not investment advice · Privacy Policy